-
Patent Agency Ranking
公开(公告)号：US11945787B2
公开(公告)日：2024-04-02
申请号：US17201201
申请日：2021-03-15
Applicant: Ela Pharma Ltd
Inventor： Ilana Nathan , Boris Khalfin
IPC: C07D233/04 , A61K31/00 , A61K31/167 , A61K31/4045 , A61K31/415 , A61K31/4178 , A61K31/4196 , A61K31/426 , A61K31/428 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/536 , A61K45/06 , A61P25/00 , C07C233/24 , C07D233/44 , C07D233/48 , C07D265/22 , C07D275/06 , C07D277/42 , C07D277/56 , C07D405/06 , C07D417/12 , C12N5/077 , C12N15/113
CPC classification number: C07D265/22 , A61K31/00 , A61K31/167 , A61K31/4045 , A61K31/415 , A61K31/4178 , A61K31/4196 , A61K31/426 , A61K31/428 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/536 , A61K45/06 , A61P25/00 , C07C233/24 , C07D233/44 , C07D233/48 , C07D275/06 , C07D277/42 , C07D277/56 , C07D405/06 , C07D417/12 , C12N5/0669 , C12N15/1137 , C12Y304/14001 , C12Y304/21036 , C12N2310/14 , C12N2501/30 , C12N2501/999
Abstract: Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising the same, and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis are described. The compounds include imidazoles of Formula VI:
wherein G1 is pyrrolidine, pyrazolidine, imidazolidine piperidine, or piperazine and G2 is alkyl, cycloalkyl, heterocycle, or aryl. The pyrrolidine, pyrazolidine, imidazolidine, piperidine, or piperazine of G1 and the alkyl, cycloalkyl, heterocycle, or aryl of G2 are optionally substituted with one or more substituents independently selected from the group consisting of halogen, NO2, CN, C1-C6 alkyl, C1-C6 haloalkyl, NH2, OH, OC1-C6 alkyl, C(O)H, C(O)C1-C6 alkyl, C(O)NH2, C(O)OH, and C(O)OC1-C6 alkyl. Variations applications for the described compounds, and combination therapies are further described as well.-
公开(公告)号：US20210309620A1
公开(公告)日：2021-10-07
申请号：US17201201
申请日：2021-03-15
Applicant: Ela Pharma Ltd
Inventor： Ilana Nathan , Boris Khalfin
IPC: C07D265/22 , A61K31/4178 , A61K31/426 , A61K31/454 , C07D277/42 , C12N15/113 , A61K31/00 , A61K31/496 , A61K31/415 , C07D405/06 , C07D277/56 , A61K31/4439 , C07D233/44 , C07D417/12 , A61K31/4196 , A61K31/4045 , A61P25/00 , A61K31/167 , A61K31/428 , A61K31/536 , A61K45/06 , C07C233/24 , C07D233/48 , C07D275/06 , C12N5/077
Abstract: Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.
-
公开(公告)号：US10968185B2
公开(公告)日：2021-04-06
申请号：US15564836
申请日：2016-04-07
Applicant: ELA PHARMA LTD
Inventor： Ilana Nathan , Boris Khalfin
IPC: A61K31/427 , C07D277/20 , C07D265/22 , A61K31/4178 , A61K31/426 , A61K31/454 , C07D277/42 , C12N15/113 , A61K31/00 , A61K31/496 , A61K31/415 , C07D405/06 , C07D277/56 , A61K31/4439 , C07D233/44 , C07D417/12 , A61K31/4196 , A61K31/4045 , A61P25/00 , A61K31/167 , A61K31/428 , A61K31/536 , A61K45/06 , C07C233/24 , C07D233/48 , C07D275/06 , C12N5/077
Abstract: Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis are described. The compounds include thiazoles of Formula II, where G1 is an optionally substituted pyrrolidine, an optionally substituted pyridine, an optionally substituted aryl, an optionally substituted piperidine, an optionally substituted piperazine, an optionally substituted imidazolidine, or an optionally substituted pyrazolidine. G3 is or G3 is an optionally substituted alkyl, an optionally substituted aryl or an optionally cyloalkyl. G2 is an optionally substituted alkyl, an optionally substituted aryl, an optionally substituted cyloalkyl or an optionally substituted heterocycle. Various applications for the described compounds, and combination therapies are described as well.
-
公开(公告)号：US20240294480A1
公开(公告)日：2024-09-05
申请号：US18414456
申请日：2024-01-16
Applicant: Ela Pharma Ltd
Inventor： Ilana Nathan , Boris Khalfin
IPC: C07D265/22 , A61K31/00 , A61K31/167 , A61K31/4045 , A61K31/415 , A61K31/4178 , A61K31/4196 , A61K31/426 , A61K31/428 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/536 , A61K45/06 , A61P25/00 , C07C233/24 , C07D233/44 , C07D233/48 , C07D275/06 , C07D277/42 , C07D277/56 , C07D405/06 , C07D417/12 , C12N5/077 , C12N15/113
CPC classification number: C07D265/22 , A61K31/00 , A61K31/167 , A61K31/4045 , A61K31/415 , A61K31/4178 , A61K31/4196 , A61K31/426 , A61K31/428 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/536 , A61K45/06 , A61P25/00 , C07C233/24 , C07D233/44 , C07D233/48 , C07D275/06 , C07D277/42 , C07D277/56 , C07D405/06 , C07D417/12 , C12N5/0669 , C12N15/1137 , C12Y304/14001 , C12Y304/21036 , C12N2310/14 , C12N2501/30 , C12N2501/999
Abstract: Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.
-
公开(公告)号：US20180312477A1
公开(公告)日：2018-11-01
申请号：US15564836
申请日：2016-04-07
Applicant: ELA PHARMA LTD
Inventor： Ilana Nathan , Boris Khalfin
IPC: C07D265/22 , A61K45/06 , C12N5/077 , A61P25/00 , A61K31/426 , A61K31/536 , C07D277/42 , C07D233/48 , A61K31/4178 , C07C233/24 , A61K31/167 , C07D275/06 , A61K31/428 , A61K31/454
CPC classification number: A61K31/496 , A61K31/00 , A61K31/4045 , A61K31/415 , A61K31/4178 , A61K31/4196 , A61K31/426 , A61K31/4439 , A61K31/454 , C07D233/44 , C07D277/42 , C07D277/56 , C07D405/06 , C07D417/12 , C12N15/1137 , C12N2310/14 , C12Y304/14001 , C12Y304/21036
Abstract: Inhibitor compounds and agents of Cathepsin C, CELA1, CELA3A and/or structurally related molecules thereto, compositions comprising same and uses thereof in the inhibition and/or prevention of cell and/or tissue necrosis is described. Various applications for the described compounds, and combination therapies are described as well.
-
-
-
-
Search Results
5
records
(took 0.042 seconds)
